ANTIHISTAMINE TUMOR-PROMOTION EPIDEMIOLOGY STUDIES UNDER CONSIDERATION
This article was originally published in The Tan Sheet
Executive Summary
ANTIHISTAMINE TUMOR-PROMOTION EPIDEMIOLOGY STUDIES UNDER CONSIDERATION by FDA in response to a study published in the May 18 Journal of the National Cancer Institute that found that three prescription antihistamines -- Schering-Plough's Claritin (loratadine), Janssen's Hismanal (astemizole) and Pfizer's Atarax (hydroxyzine) -- stimulate the growth of tumors in mice. In a May 17 "Talk Paper," FDA said it "is evaluating the feasibility of epidemiologic studies in patients with cancer."